These devices, that can detect the electrical activity of the brain, are currently being tested in animals by measuring their brain activity using Graphene transitors and could have therapeutic applications, as well as allowing the design of new brain-machine interfaces.

NANBIOSIS Coordinator, Jesús Izco, participated in the Round Table: “Promoting Innovation in ICTS” to explain the experience of NANBIOSIS. He spoke of the establishment of the ICTS, its portfolio of services and dissemination plan as means to achieve their maximum objective of innovation and transfer of technology developed through the Platform.

The forum brought together more than 2000 people, 120 speakers, 23 countries, 500 companies and institutions, 190 research groups, 40 universities and 37 technological platforms with more than 1,900 technological projects and represents an excellent opportunity for:

Due to the recent publication of the call Retos–Colaboración 2016, of the State Program of I + D + i, the Technology Platforms in the field of Health, in collaboration with the MINECO organized on February, 4th 2016, an Info Day in order to:

To encourage the participation of companies and research centers

To generate R & D proposals for the formation of consortia

To hold bilateral meetings to review proposals

The event included an informative part on the details of the call and a block of proposals and success stories. NANBIOSIS Coordinator, Jesús Izco, presented NANBIOSIS as an entity supporting R & D in collaboration, explaining how the Platform was developed to become part of the National Map of ICTS (Singular Scientific and Technical Infrastructures) and its range of services for the development of R + D + I.

The NANBIOSIS infrastructure is mainly engaged in research in the health field but from a more transversal and technological point of view than other research centres, with a relevant specialization in biomaterials and tissue engineering, bioengineering and nanomedicine and molecular diagnostics view. That more technological and finalist positioning in the health field, together with the excellence of researchers who coordinate the several units that make up the platform, situates NANBIOSIS as a benchmark for research projects and transfer.

JUMISC carried out an in vitro and in vivo study focused in the use of MSCs -coated surgical meshes to counteract the inflammatory response commonly observed after implantation.
Surgical meshes are medical devices traditionally used to solve hernias and prolapsed organs pathologies that may cause inflammation and foreign body reactions, causing pain and discomfort to the patient.
According to this, the JUMISC financed a R&D project to evaluate if MSCs may provide an anti-inflammatory environment after surgical implantation.
Magnetic resonance imaging, laparoscopic evaluation and histological studies were performed to evaluate safety aspects and its future clinical application as a bioactive material. The in vivo results demonstrated that they fulfill safety aspects and non-adverse effects.
The results have been published in Acta Biomaterialia, the second best journal in its area, whose authors are Rebeca Blázquez, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Alejandra Usón y Javier G. Casado. Moreover, according to the philosophy of JUMISC to promote the innovation and the quality of the patient life, from these results emerged an invention which is protected as a patent.
Finally, this project will continue and future experiments will be developed in a clinically relevant animal model for the extrapolation of the results to a clinical scenario.